GLG News by Neonatal-Perinatal Physicians

Glaxo's new pandemic flu vaccine was just approved for sale and use in the EU.  It has or is trying to establish contracts with multiple countries to supply stockpiles with values in the 100's of millions

This article summarizes in a concise format what most of us do anyway. Nonetheless, it is good to have the steps clearly spelled out.    

I'd go with the second analyst in the article, who points out the exosting product overlap between the two companies.

The major effect, I would hope, would be to keep people from using unlicensed practitioners to do unapproved procedures with inappropriate products.

Strattera has been approved for "maintenance treatment" for ADHD, however this probably changes nothing for prescribers or patients.  Those who are on it will continue to take it, but no one will be changing to Strattera because of this new classification.

While this is new data from an 18 month study, the common practice already is to "stick with what works." Thus, if a child is started on Strattera (or another ADHD medication) and has positive results, the physician will most likely continue that drug.

Although just a press release, the itself study is interesting. The attempt to modify the symptoms of ADHD by affecting neurotransmitter release or reuptake is not new, but this is an attempt to do so via a novel receptor pathway.

we really have had little luck with straterra in  our office.  Even at high  doses,  the drug rarely does the trick

the vaccines may be similar, but I'll stick with the Merck product

what goes up must come down.  This speculation in oil has happened many times during my lifetime and it is the same with all commodites (remember the holland tulips).  Yes, many have and will make fortunes in commoditiy trades, but in the end the real intrinsic value comes through.  When...